Details of the Drug Combinations

General Information of This Drug (ID: DMV7YFT)

Drug Name

Darolutamide DMV7YFT

Synonyms

1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PF-05212384 + Darolutamide	DCAEQ4W	PF-05212384	MCRPC (Metastatic Castration-resistant Prostate Cancer)	[2]
Darolutamide + Dasatinib	DCSSVAO	Dasatinib	Metastatic Prostate Cancer	[3]
Degarelix + Darolutamide	DCFZAHV	Degarelix	Prostate Cancer	[4]
Goserelin + Darolutamide	DCVGCYP	Goserelin	Salivary Gland Cancer	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	ClinicalTrials.gov (NCT06190899) Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
3	ClinicalTrials.gov (NCT04925648) Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
4	ClinicalTrials.gov (NCT04176081) Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
5	ClinicalTrials.gov (NCT05694819) Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)